Hidrazin

Gold J. Hydrazine sulfate: a current perspective. Nutrition and cancer. 1987;9(2-3):59-66.
Vasudeva M, Vashishat RK. Mutagenic and recombinogenic activity of hydrazine sulphate in Saccharomyces cerevisiae. Mutation research. 1985;155(3):113-5.
Chlebowski RT, Bulcavage L, Grosvenor M, Oktay E, Block JB, Chlebowski JS, et al. Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990;8(1):9-15.
Toth B. A review of the antineoplastic action of certain hydrazines and hydrazine-containing natural products. In vivo (Athens, Greece). 1996;10(1):65-96.
Samuels ML, Leary WV, Alexanian R, Howe CD, Frei E, 3rd. Clinical trials with N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride in malignant lymphoma and other disseminated neoplasia. Cancer. 1967;20(8):1187-94.
Tayek JA, Sutter L, Manglik S, Lillington LB, Grosvenor M, Chlebowski RT. Altered metabolism and mortality in patients with colon cancer receiving chemotherapy. The American journal of the medical sciences. 1995;310(2):48-55.
Gold J. Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients. Oncology. 1975;32(1):1-10.
Dills WL, Jr. Nutritional and physiological consequences of tumour glycolysis. Parasitology. 1993;107 Suppl:S177-86.
Johnson DC, Freudenberg MA, Jia F, Gonzalez JC, Galanos C, Morrison DC, et al. Contribution of tumor necrosis factor-alpha and glucocorticoid in hydrazine sulfate-mediated protection against endotoxin lethality. Circulatory shock. 1994;43(1):1-8.
Bruera E. Current pharmacological management of anorexia in cancer patients. Oncology (Williston Park, NY). 1992;6(1):125-30; discussion 32, 37.
Tayek JA, Heber D, Chlebowski RT. Effect of hydrazine sulphate on whole-body protein breakdown measured by 14C-lysine metabolism in lung cancer patients. Lancet (London, England). 1987;2(8553):241-4.
Kosty MP, Fleishman SB, Herndon JE, 2nd, Coughlin K, Kornblith AB, Scalzo A, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994;12(6):1113-20.
Kimball RF. The mutagenicity of hydrazine and some of its derivatives. Mutation research. 1977;39(2):111-26.
Dingess O, Cupp MJ, Tracy TS. Hydrazine Sulfate. In: Cupp MJ, Tracy TS, editors. Dietary Supplements: Toxicology and Clinical Pharmacology. Totowa, NJ: Humana Press; 2003. p. 253-66.
Hainer MI, Tsai N, Komura ST, Chiu CL. Fatal hepatorenal failure associated with hydrazine sulfate. Annals of internal medicine. 2000;133(11):877-80.
National Cancer Institute (October 1999), "Hydrazine Sulfate", PDQ Complementary/Alternative Medicine